Catalysts / ENSC
Upcoming FDA decisions and readouts we track for Ensysce Biosciences, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Ensysce Biosciences (ENSC, listed on Nasdaq). It concerns CY-200 (Complex regional pain syndrome type 1).
First on the list: the Phase 2 readout for CY-200 (Complex regional pain syndrome type 1), guided by the company to H2 2026.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Ensysce Biosciences ENSC · Nasdaq | CY-200 | Complex regional pain syndrome type 1 | H2 2026 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | No |
FreeBioList